These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 33917428)
1. Novel and Potent Small Molecules against Melanoma Harboring BRAF Class I/II/III Mutants for Overcoming Drug Resistance. Kim N; Shin I; Lee J; Jeon E; Kim Y; Ryu S; Ju E; Cho W; Sim T Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33917428 [TBL] [Abstract][Full Text] [Related]
2. The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations. Choi SH; Shin I; Kim N; Nam Y; Sim T Biochem Biophys Res Commun; 2020 Nov; 532(2):315-320. PubMed ID: 32873393 [TBL] [Abstract][Full Text] [Related]
3. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
4. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251 [TBL] [Abstract][Full Text] [Related]
6. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467 [TBL] [Abstract][Full Text] [Related]
7. Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463 [No Abstract] [Full Text] [Related]
8. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853 [TBL] [Abstract][Full Text] [Related]
9. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma. Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552 [TBL] [Abstract][Full Text] [Related]
10. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A. Mazzio EA; Soliman KFA Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076 [TBL] [Abstract][Full Text] [Related]
11. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. Dankner M; Lajoie M; Moldoveanu D; Nguyen TT; Savage P; Rajkumar S; Huang X; Lvova M; Protopopov A; Vuzman D; Hogg D; Park M; Guiot MC; Petrecca K; Mihalcioiu C; Watson IR; Siegel PM; Rose AAN Clin Cancer Res; 2018 Dec; 24(24):6483-6494. PubMed ID: 29903896 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489 [TBL] [Abstract][Full Text] [Related]
13. Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. Mologni L; Costanza M; Sharma GG; Viltadi M; Massimino L; Citterio S; Purgante S; Raman H; Pirola A; Zucchetti M; Piazza R; Gambacorti-Passerini C Neoplasia; 2018 May; 20(5):467-477. PubMed ID: 29605720 [TBL] [Abstract][Full Text] [Related]
14. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation. Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149 [TBL] [Abstract][Full Text] [Related]
16. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model. Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821 [TBL] [Abstract][Full Text] [Related]
17. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656 [TBL] [Abstract][Full Text] [Related]
18. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830 [TBL] [Abstract][Full Text] [Related]
19. Acquisition of resistance to vemurafenib leads to interleukin-10 production through an aberrant activation of Akt in a melanoma cell line. Inozume T; Tsunoda T; Morisaki T; Harada K; Shirasawa S; Kawamura T J Dermatol; 2018 Dec; 45(12):1434-1439. PubMed ID: 30222203 [TBL] [Abstract][Full Text] [Related]
20. The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas. Peh J; Fan TM; Wycislo KL; Roth HS; Hergenrother PJ Mol Cancer Ther; 2016 Aug; 15(8):1859-69. PubMed ID: 27297867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]